PCRX
Pacira BioSciences, Inc.
24.70$
+2.4%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 65.7% | 64.8% | 62.1% | 62.2% | 69.3% | 49.2% | 51.1% | 41.7% | 29.6% | 32.4% | 48.0% | 43.3% | |
| 48.5% | 40.8% | 9.2% | 8.6% | 19.2% | 9.4% | 7.8% | 28.2% | 6.2% | 9.7% | 17.8% | 12.5% | |
| 48.5% | 40.8% | 44.1% | 49.5% | 55.6% | 35.1% | 40.9% | 31.6% | 17.2% | 17.7% | 31.2% | 18.8% | |
| 6.9% | 6.6% | 7.6% | 5.0% | 5.5% | 5.7% | 4.2% | 4.6% | 5.9% | 6.7% | 7.3% | 9.8% | |
| 9.0% | 15.8% | 8.0% | 6.6% | 7.0% | 7.0% | 5.1% | 4.7% | 5.7% | 6.6% | 8.1% | 12.1% | |
| 18.6% | 23.2% | 25.8% | 17.0% | 15.8% | 12.6% | 10.7% | 12.8% | 15.1% | – | – | – | |
| 7.3% | 7.9% | 11.9% | 8.8% | 9.0% | 12.0% | 7.8% | 7.0% | 9.7% | 10.4% | 0.0% | 1.6% | |
| 0.1% | 0.0% | 11.9% | 8.8% | – | 12.6% | 7.6% | 30.1% | 32.2% | 30.7% | 27.4% | 29.1% | |
| 47.5% | 43.9% | 44.1% | 55.5% | 53.4% | 57.3% | 51.4% | 64.8% | 53.9% | 44.7% | 49.9% | 45.2% | |
| 42.9% | 38.9% | 11.5% | 8.9% | 8.8% | 13.0% | 19.9% | 25.1% | 8.8% | 6.2% | 19.9% | 9.5% | |
| 31.7% | 26.7% | 27.8% | 0.1% | 0.0% | 0.6% | 12.3% | 18.4% | 2.5% | 1.1% | 13.6% | 0.8% | |
| 2.1% | 2.2% | 1.9% | 2.3% | 2.1% | 1.5% | 0.8% | 0.5% | 0.9% | 1.0% | 1.2% | 1.2% | |
| 0.0% | 0.0% | 27.8% | 44.0% | 42.2% | 36.8% | 24.6% | 32.5% | 39.0% | 32.6% | 24.7% | 29.4% | |
| 52.5% | 56.1% | 55.9% | 44.5% | 46.6% | 42.7% | 48.6% | 35.2% | 46.1% | 55.3% | 50.1% | 54.8% | |
| -95.1% | -79.1% | -88.4% | -61.9% | -56.3% | -48.1% | -19.9% | -10.2% | -8.8% | -6.8% | -13.3% | -15.8% | |
| 10.8% | 10.6% | 9.5% | 6.3% | 5.9% | 5.0% | 3.4% | 2.2% | 2.8% | 3.3% | 3.0% | 3.6% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.